Quoting from the article by Greg Avery:"The No. 1 reason venture capitalists shy away from domestic biotech startups and are increasingly investing overseas is the unpredictability of the U.S. Food and Drug Administration approval process, according to a recent survey...
'New novel treatments are dying on the vine because they can’t get approval quick enough,' said Holli Riebel, CEO of the Colorado BioScience Association. 'If we’re going to develop cures to major diseases, we’re going to have to finance new drugs and major devices.'"
Link to the Denver Business Journal
No comments:
Post a Comment